Advances in Blood Flow Quantification Methods for Diagnosis, Monitoring, Prediction, and Personalized Treatment of Cardiovascular Disease explains how abnormal hemodynamics (blood flow dynamics) greatly alter the cardiovascular system’s ability to transport, control and maintain blood flow throughout the body. These deviations often lead to the initiation and progression of disease. Notably, hemodynamic quantification can be extremely useful for accurate and early diagnosis of cardiovascular disease. Particularly, the ability to monitor and predict hemodynamic effects following specific interventions can significantly broaden lifesaving options. However, image-based computational modelling of predictive hemodynamics analysis methods (and therefore new diagnostic tools) are rare. By extending quantitative methods of analysis, medical professionals can foresee effects of various cardiovascular interventions, allowing for optimized, situation-based care.
Advances in Blood Flow Quantification Methods for Diagnosis, Monitoring, Prediction, and Personalized Treatment of Cardiovascular Disease posits that novel, image-based computational modelling hemodynamic analysis tools will enable the next generation of diagnosis, predictive, and treatment planning resources for cardiovascular disease. Readers will become well-versed in recent advances in hemodynamic approaches, while preparing themselves for the next wave of revolutions in cardiovascular health.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
- Introduction
- Hemodynamics: Fundamentals and roles in atrial fibrillation
- Advances in blood flow quantification methods for diagnosis and monitoring of cardiovascular disease
- Advances in blood flow quantification methods for prediction of cardiovascular interventions
- Computational predictive modeling of valve performance and risks toward personalization of TAVR with lifetime management
- Advances in 4D flow MRI blood flow quantification methods for prediction of cardiovascular intervention
- Advancing clinical interventions through patient-specific in-vitro simulators: Challenges, techniques and future directions
- Enhancing patient management with TAVR and coronary disease through computational modeling
- Impact of flow in assessment and prognosis of valvular heart diseases
- Translational machine learning in cardiac disease: Advancing diagnosis, monitoring, and prediction
- Bridging the critical gap in cardiovascular biomechanics: From computational models to clinical applications
Authors
Zahra Keshavarz Motamed Associate Professor, Department of Mechanical Engineering, McMaster University, Canada.Dr. Zahra K. Motamed PhD, MSc, directs the Cardiovascular Research Group and is an Associate Professor in the Department of Mechanical Engineering at McMaster University. She is a member of the Professional Engineers of Ontario, with over 17 years of experience in cardiovascular diseases and their devices. She served as the Chair of the 2021 NSERC Research Tool and Instruments Selection Committee for Mechanical Engineering. She is on the editorial board of Scientific Reports, and for the Journal of Frontiers in Bioengineering and Biotechnology.
She was a handling Editor in Frontiers in Cardiovascular Medicine. She is currently the invited lead guest editor of Frontiers in Bioengineering and Biotechnology, and an invited guest editor of Scientific Reports (a Nature journal). Her research interests are mainly in the areas of computational fluid dynamics for the study of cardiovascular disease, translational and basic cardiovascular mechanics, and developing quantitative diagnostic, predictive, and intervention-optimization tools.
Jose M. de La Torre Hern�ndez Hospital Universitario Marques de Valdecilla, Spain.Jose M. de La Torre Hern�ndez MD, PhD, FESC is an interventional cardiologist and head of the Hemodynamics and Interventional Department of the Marques de Valdecilla University of Santander. He is the president of the Spanish Society of Cardiology, and is a fellow of the European Society of Cardiology. Dr. Hern�ndez is the former associate director of the Trans Catheter Therapeutics and TCT conferences (USA).
Dr. Hern�ndez has participated in over 75 clinical trials for cardiac devices and has been an author in more than 220 peer-reviewed papers and 7 book chapters. Dr. Hern�ndez currently serves as the Founder and Editor in Chief of REC: Interventional Cardiology, editorial consultant in JACC Interventions and section editor in Eurointervention. Dr. Hern�ndez brings a vast clinical insight essential to the success of this book, specifically in terms of future clinical device adoptability.
Philippe Pibarot Universit� Laval, Canada.Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC, FCCS is a professor in the Department of Medicine at Laval University, holds the Canada Research Chair in Valvular Heart Disease, and is head of Cardiology Research at Qu�bec Heart & Lung Institute (IUCPQ). He is principal investigator in studies and trials funded by a grant from the Canadian Institutes of Health Research, and directs the Echocardiography Core Laboratory at IUCPQ.
He is associate editor for the Structural Heart and Eurointervention journals, Imaging section editor for the Journal of the American College of Cardiology, and Editor-in-Chief of the Journal of the Heart Valve Society. He received the Annual Achievement Award of the Canadian Society of Echocardiography, the Canadian Cardiovascular Society Research Achievement Award, the Feigenbaum Lecture Award, and the CIHR-ICRH/CCS Distinguished Lecturer Award in Cardiovascular Sciences. His research program develops and validates patient-oriented approaches to improve diagnosis, prevention, and treatment of VHD.
